Disclosure from Vaping Professionals Wanted: Exciting Rewards Await!

Industry Insight by 2FIRSTS
Jan.16.2024
Disclosure from Vaping Professionals Wanted: Exciting Rewards Await!
Rewards ranging from CN¥200 to CN¥1000 for adopted releases of information. Looking forward to your participation!

To obtain first-hand industry information, 2FIRSTS is thrilled to announce the launch of a rewarding tip-off initiative starting from January 16th. We have established a dedicated mailbox to encourage professionals within the industry to share exclusive leads in exchange for attractive rewards.

 

The information you provide can include, but is not limited to, industry dynamics, market insights, unforeseen events, company developments, and more. As long as your tip meets our requirements, 2FIRSTS will promptly assign editors to follow up, ensuring that the information receives timely attention.

 

Upon verification and adoption of the tip, the informant stands a chance to receive cash rewards ranging from ¥200 to ¥1000 (amounts may vary). In case of duplicate tips, only the first informant will be eligible for the reward.

 

Terms and Conditions:

 

Time Frame: 

Effective from January 16, 2023, ongoing.

 

Reward Mechanism: 

Cash rewards ranging from ¥200 to ¥1000 for adopted tips (only the first informant will be rewarded in case of duplicate tips).

 

Tip-off Content: 

Inclusive of, but not limited to, industry dynamics, market information, unforeseen events, company movements within the electronic cigarette industry.

 

Participation Method: 

If you are a professional in the e-cigarette industry, simply send the crucial information you possess to our dedicated email address [info@2firsts.com]. We will promptly follow up on your tip.

 

Through this interactive platform, we look forward to establishing closer connections with industry professionals and collectively driving the development of the vaping industry. We appreciate everyone's continuous support for 2FIRSTS and eagerly await your active participation in creating more enriching and accurate industry content!

 

2FIRSTS Editorial Department

 


About 2FIRSTS

 

Established in early 2022, 2FIRSTS is a globally influential aerosol technology media and think tank. Our core readership includes regulatory authorities from various countries, international new tobacco companies, distributors, supply chain enterprises, non-profit organizations, and media outlets. 2FIRSTS brings readers the latest global information, forward-thinking topics, in-depth analyses, insights, and rich data and information. We are committed to promoting high-quality development of the global new tobacco industry through media and research, contributing to harm reduction initiatives worldwide.

 

2FIRSTS has currently established platforms such as 2firsts.cn (Chinese), 2firsts.com (International), and 2firsts.com/es (Spanish), with a daily visitation exceeding 10,000.

 

With offices in Shenzhen, Hong Kong, New York, Europe, and collaborations with international new tobacco companies, regulatory authorities, and media outlets, 2FIRSTS maintains excellent cooperation and close communication. We are also proud partners and official media representatives for major global new tobacco exhibitions.

South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's Ministry of Gender Equality and Family said on September 14 that it plans to designate unmanned e-cigarette stores as businesses where minors are prohibited from entering or working. Operators would be required to verify customers' ages and display notices restricting access by minors. The proposal is open for public comment through October 6. The move follows an April expansion of South Korea's statutory tobacco definition that brought products made with natural or synthetic nicotine under the Tobacco Business Act. Nicotine-free liquids and products using nicotine analogues such as 6-methylnicotine, however, remain an emerging regulatory issue.
Sep.21
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Documents obtained by 2Firsts show that Sweden's Public Health Agency ordered Swedish Match to revise ingredient labels beyond the five ZYN products inspected. The dispute centers on whether flavoring ingredients must be individually disclosed, with Swedish Match citing trade-secret protection and the regulator insisting on full ingredient disclosure. The company faces a conditional penalty of SEK 2 million per month for noncompliance. As of October 22, the agency had received no appeal, despite the company's stated intention to challenge the decision.
Oct.22
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI nicotine pouch brand Nordic Spirit has entered a long-term partnership with Manchester’s Co-op Live, becoming the venue’s Official Nicotine Pouch Partner. The 23,500-capacity venue is the UK’s largest indoor live entertainment arena. Nordic Spirit will run in-venue activations for existing adult nicotine consumers and sell products at selected arena bars. The agreement was entered into before the relevant UK sponsorship restrictions were introduced, while the government intends to implement a comprehensive ban on advertising and sponsorship of vaping and nicotine products from June 1, 2027.
Sep.07
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22